217 related articles for article (PubMed ID: 18239620)
1. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
[TBL] [Abstract][Full Text] [Related]
2. NGS better discriminates true MRD positivity for the risk stratification of childhood ALL treated on an MRD-based protocol.
Svaton M; Skotnicova A; Reznickova L; Rennerova A; Valova T; Kotrova M; van der Velden VHJ; Brüggemann M; Darzentas N; Langerak AW; Zuna J; Stary J; Trka J; Fronkova E
Blood; 2023 Feb; 141(5):529-533. PubMed ID: 36240445
[TBL] [Abstract][Full Text] [Related]
3. Relationship between subtype-specific minimal residual disease level and long-term prognosis in children with acute lymphoblastic leukemia.
Huang XT; Wang CJ; Gao C; Xue TL; Zhao ZJ; Wang TY; Wu MY; Cui L; Zhang RD; Li ZG
Ann Hematol; 2024 Mar; ():. PubMed ID: 38494553
[TBL] [Abstract][Full Text] [Related]
4. FCM marker importance for MRD assessment in T-cell acute lymphoblastic leukemia: An AIEOP-BFM-ALL-FLOW study group report.
Kowarsch F; Maurer-Granofszky M; Weijler L; Wödlinger M; Reiter M; Schumich A; Feuerstein T; Sala S; Nováková M; Faggin G; Gaipa G; Hrusak O; Buldini B; Dworzak MN
Cytometry A; 2024 Jan; 105(1):24-35. PubMed ID: 37776305
[TBL] [Abstract][Full Text] [Related]
5. Minimal residual disease predicts outcomes in KMT2A-rearranged but not KMT2A-germline infant acute lymphoblastic leukemia: Report from Children's Oncology Group study AALL0631.
Faulk KE; Kairalla JA; Dreyer ZE; Carroll AJ; Heerema NA; Devidas M; Carroll WL; Raetz EA; Loh ML; Hunger SP; Borowitz M; Wang C; Guest E; Brown PA
Pediatr Blood Cancer; 2023 May; ():e30467. PubMed ID: 37259259
[TBL] [Abstract][Full Text] [Related]
6. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines.
van der Velden VHJ; Dombrink I; Alten J; Cazzaniga G; Clappier E; Drandi D; Eckert C; Fronkova E; Hancock J; Kotrova M; Kraemer R; Montonen M; Pfeifer H; Pott C; Raff T; Trautmann H; Cavé H; Schäfer BW; van Dongen JJM; Trka J; Brüggemann M;
Leukemia; 2024 May; ():. PubMed ID: 38744919
[TBL] [Abstract][Full Text] [Related]
7. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
Conter V; Valsecchi MG; Cario G; Zimmermann M; Attarbaschi A; Stary J; Niggli F; Dalla Pozza L; Elitzur S; Silvestri D; Locatelli F; Möricke A; Engstler G; Smisek P; Bodmer N; Barbaric D; Izraeli S; Rizzari C; Boos J; Buldini B; Zucchetti M; von Stackelberg A; Matteo C; Lehrnbecher T; Lanvers-Kaminsky C; Cazzaniga G; Gruhn B; Biondi A; Schrappe M
J Clin Oncol; 2024 Mar; 42(8):915-926. PubMed ID: 38096462
[TBL] [Abstract][Full Text] [Related]
8. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.
Conter V; Bartram CR; Valsecchi MG; Schrauder A; Panzer-Grümayer R; Möricke A; Aricò M; Zimmermann M; Mann G; De Rossi G; Stanulla M; Locatelli F; Basso G; Niggli F; Barisone E; Henze G; Ludwig WD; Haas OA; Cazzaniga G; Koehler R; Silvestri D; Bradtke J; Parasole R; Beier R; van Dongen JJ; Biondi A; Schrappe M
Blood; 2010 Apr; 115(16):3206-14. PubMed ID: 20154213
[TBL] [Abstract][Full Text] [Related]
9. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.
Schrappe M; Valsecchi MG; Bartram CR; Schrauder A; Panzer-Grümayer R; Möricke A; Parasole R; Zimmermann M; Dworzak M; Buldini B; Reiter A; Basso G; Klingebiel T; Messina C; Ratei R; Cazzaniga G; Koehler R; Locatelli F; Schäfer BW; Aricò M; Welte K; van Dongen JJ; Gadner H; Biondi A; Conter V
Blood; 2011 Aug; 118(8):2077-84. PubMed ID: 21719599
[TBL] [Abstract][Full Text] [Related]
10. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease in acute lymphoblastic leukemia.
Campana D
Hematology Am Soc Hematol Educ Program; 2010; 2010():7-12. PubMed ID: 21239764
[TBL] [Abstract][Full Text] [Related]
12. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000.
Möricke A; Zimmermann M; Reiter A; Henze G; Schrauder A; Gadner H; Ludwig WD; Ritter J; Harbott J; Mann G; Klingebiel T; Zintl F; Niemeyer C; Kremens B; Niggli F; Niethammer D; Welte K; Stanulla M; Odenwald E; Riehm H; Schrappe M
Leukemia; 2010 Feb; 24(2):265-84. PubMed ID: 20010625
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
[TBL] [Abstract][Full Text] [Related]
14. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.
Brüggemann M; Schrauder A; Raff T; Pfeifer H; Dworzak M; Ottmann OG; Asnafi V; Baruchel A; Bassan R; Benoit Y; Biondi A; Cavé H; Dombret H; Fielding AK; Foà R; Gökbuget N; Goldstone AH; Goulden N; Henze G; Hoelzer D; Janka-Schaub GE; Macintyre EA; Pieters R; Rambaldi A; Ribera JM; Schmiegelow K; Spinelli O; Stary J; von Stackelberg A; Kneba M; Schrappe M; van Dongen JJ; ;
Leukemia; 2010 Mar; 24(3):521-35. PubMed ID: 20033054
[TBL] [Abstract][Full Text] [Related]
15. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
Möricke A; Reiter A; Zimmermann M; Gadner H; Stanulla M; Dördelmann M; Löning L; Beier R; Ludwig WD; Ratei R; Harbott J; Boos J; Mann G; Niggli F; Feldges A; Henze G; Welte K; Beck JD; Klingebiel T; Niemeyer C; Zintl F; Bode U; Urban C; Wehinger H; Niethammer D; Riehm H; Schrappe M;
Blood; 2008 May; 111(9):4477-89. PubMed ID: 18285545
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease after induction is the strongest predictor of prognosis in intermediate risk relapsed acute lymphoblastic leukaemia - long-term results of trial ALL-REZ BFM P95/96.
Eckert C; von Stackelberg A; Seeger K; Groeneveld TW; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Escherich G; Henze G
Eur J Cancer; 2013 Apr; 49(6):1346-55. PubMed ID: 23265714
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease in acute lymphoblastic leukemia: optimal methods and clinical relevance, pitfalls and recent approaches.
Salari F; Shahjahani M; Shahrabi S; Saki N
Med Oncol; 2014 Nov; 31(11):266. PubMed ID: 25287907
[TBL] [Abstract][Full Text] [Related]
19. Postinduction minimal residual disease monitoring by polymerase chain reaction in children with acute lymphoblastic leukemia.
Paganin M; Fabbri G; Conter V; Barisone E; Polato K; Cazzaniga G; Giraldi E; Fagioli F; Aricò M; Valsecchi MG; Basso G
J Clin Oncol; 2014 Nov; 32(31):3553-8. PubMed ID: 25287825
[TBL] [Abstract][Full Text] [Related]
20. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.
Basso G; Veltroni M; Valsecchi MG; Dworzak MN; Ratei R; Silvestri D; Benetello A; Buldini B; Maglia O; Masera G; Conter V; Arico M; Biondi A; Gaipa G
J Clin Oncol; 2009 Nov; 27(31):5168-74. PubMed ID: 19805690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
